<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/80DD41C8-30F5-4AB5-A2F4-F3285B212F89"><gtr:id>80DD41C8-30F5-4AB5-A2F4-F3285B212F89</gtr:id><gtr:name>Johns Hopkins Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF"><gtr:id>C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF</gtr:id><gtr:name>Centers for Disease Control and Prevention (CDC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D4584B27-3F2A-4408-B3E3-19B6800F5217"><gtr:id>D4584B27-3F2A-4408-B3E3-19B6800F5217</gtr:id><gtr:name>Amsterdam Institute for Global Health and Development (AIGHD)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E27575EF-ABFB-484B-BEEF-53343150A49E"><gtr:id>E27575EF-ABFB-484B-BEEF-53343150A49E</gtr:id><gtr:name>Bill and Melinda Gates Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/BF94AA14-BBB6-40D1-8FBC-94CF531FE138"><gtr:id>BF94AA14-BBB6-40D1-8FBC-94CF531FE138</gtr:id><gtr:name>Intellectual Ventures</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/59009362-2031-43D7-964D-8905CBE322A2"><gtr:id>59009362-2031-43D7-964D-8905CBE322A2</gtr:id><gtr:name>Government of Vietnam</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/734F19C1-61E5-45B1-A183-63FDD145328F"><gtr:id>734F19C1-61E5-45B1-A183-63FDD145328F</gtr:id><gtr:name>World Health Organization (WHO)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/60A58486-11F0-4734-B965-4238C3892F39"><gtr:id>60A58486-11F0-4734-B965-4238C3892F39</gtr:id><gtr:name>Ghana Health Service</gtr:name><gtr:address><gtr:line1>Private Mail Bag</gtr:line1><gtr:line2>Ministries</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AB534209-3172-41E0-A85E-143F22107607"><gtr:id>AB534209-3172-41E0-A85E-143F22107607</gtr:id><gtr:name>Harvard School of Public Health</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:department>Epidemiology and Population Health</gtr:department><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7"><gtr:id>055EA8B7-2C66-4FF5-96DD-63FA3AA7D0B7</gtr:id><gtr:name>London Sch of Hygiene and Trop Medicine</gtr:name><gtr:address><gtr:line1>Keppel Street</gtr:line1><gtr:postCode>WC1E 7HT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/80DD41C8-30F5-4AB5-A2F4-F3285B212F89"><gtr:id>80DD41C8-30F5-4AB5-A2F4-F3285B212F89</gtr:id><gtr:name>Johns Hopkins Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF"><gtr:id>C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF</gtr:id><gtr:name>Centers for Disease Control and Prevention (CDC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D4584B27-3F2A-4408-B3E3-19B6800F5217"><gtr:id>D4584B27-3F2A-4408-B3E3-19B6800F5217</gtr:id><gtr:name>Amsterdam Institute for Global Health and Development (AIGHD)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E27575EF-ABFB-484B-BEEF-53343150A49E"><gtr:id>E27575EF-ABFB-484B-BEEF-53343150A49E</gtr:id><gtr:name>Bill and Melinda Gates Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/BF94AA14-BBB6-40D1-8FBC-94CF531FE138"><gtr:id>BF94AA14-BBB6-40D1-8FBC-94CF531FE138</gtr:id><gtr:name>Intellectual Ventures</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/59009362-2031-43D7-964D-8905CBE322A2"><gtr:id>59009362-2031-43D7-964D-8905CBE322A2</gtr:id><gtr:name>Government of Vietnam</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/734F19C1-61E5-45B1-A183-63FDD145328F"><gtr:id>734F19C1-61E5-45B1-A183-63FDD145328F</gtr:id><gtr:name>World Health Organization (WHO)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/60A58486-11F0-4734-B965-4238C3892F39"><gtr:id>60A58486-11F0-4734-B965-4238C3892F39</gtr:id><gtr:name>Ghana Health Service</gtr:name><gtr:address><gtr:line1>Private Mail Bag</gtr:line1><gtr:line2>Ministries</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AB534209-3172-41E0-A85E-143F22107607"><gtr:id>AB534209-3172-41E0-A85E-143F22107607</gtr:id><gtr:name>Harvard School of Public Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/82F274CB-C3AA-445B-9714-3CF56785F38E"><gtr:id>82F274CB-C3AA-445B-9714-3CF56785F38E</gtr:id><gtr:name>Johns Hopkins University</gtr:name><gtr:address><gtr:line1>3400 North Charles Street</gtr:line1><gtr:line4>Baltimore</gtr:line4><gtr:line5>MD 21218</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0D82B540-D39F-46A8-BAD3-1DBBC5E6526A"><gtr:id>0D82B540-D39F-46A8-BAD3-1DBBC5E6526A</gtr:id><gtr:firstName>Trevelyan</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>McKinley</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/795687DA-AFB2-461C-A43D-74D5E6600413"><gtr:id>795687DA-AFB2-461C-A43D-74D5E6600413</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Guy</gtr:otherNames><gtr:surname>White</gtr:surname><gtr:orcidId>0000-0003-4410-6635</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3F774323-0469-4DDF-82AD-CFFC512C6285"><gtr:id>3F774323-0469-4DDF-82AD-CFFC512C6285</gtr:id><gtr:firstName>Richard John</gtr:firstName><gtr:surname>Hayes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/F4CBFE88-03F0-44EC-8AC4-F1BEE8E0BC47"><gtr:id>F4CBFE88-03F0-44EC-8AC4-F1BEE8E0BC47</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Goldstein</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/2A9A0AC6-D07B-4117-8599-866F43856B7E"><gtr:id>2A9A0AC6-D07B-4117-8599-866F43856B7E</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Vernon</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D70457EE-7904-494A-B4E9-743A28A17195"><gtr:id>D70457EE-7904-494A-B4E9-743A28A17195</gtr:id><gtr:firstName>James</gtr:firstName><gtr:surname>Wood</gtr:surname><gtr:orcidId>0000-0002-0258-3188</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C93D4522-A94C-43E0-9CDA-E3564547DE3C"><gtr:id>C93D4522-A94C-43E0-9CDA-E3564547DE3C</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:surname>Oakley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B5C2A8F2-DAD6-4AEE-BDAC-381A0037E9C5"><gtr:id>B5C2A8F2-DAD6-4AEE-BDAC-381A0037E9C5</gtr:id><gtr:firstName>Pontiano</gtr:firstName><gtr:surname>Kaleebu</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7C7FE575-9AB2-4FFD-8A6A-2BAABA124881"><gtr:id>7C7FE575-9AB2-4FFD-8A6A-2BAABA124881</gtr:id><gtr:firstName>Helen Claire</gtr:firstName><gtr:surname>Johnson</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8FE70724-1C75-4F73-AEA7-DE7EED977A65"><gtr:id>8FE70724-1C75-4F73-AEA7-DE7EED977A65</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Edmunds</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FJ005088%2F1"><gtr:id>47F164A3-241C-4D15-BF6B-87EC60FAB6ED</gtr:id><gtr:title>Calibration and analysis of complex models: methodological development and application to explore the impact of HAART in Africa</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J005088/1</gtr:grantReference><gtr:abstractText>Mathematical models are used routinely in government, the public sector, industry and academia to help predict the future and make policy decisions, such as what is the impact of ocean currents on the climate and how should we best prepare for the next flu pandemic? The usefulness of models in helping to make decision relies on how well they are can be matched to real data (model calibration) and how well we can analyse the models to find out how confident we should be about the predictions they make. In recent years models have become increasingly complex, but we don't yet have good methods to calibrate and analyse these more complicated models. The lack of these methods is a major obstacle to improving our predictions, and the policy decisions that affect all of us in the UK. 

HIV/AIDS remains the leading public health problem in much of sub-Saharan Africa. While increased access to treatment for HIV (highly active anti-retroviral therapy or HAART) has successfully reduced suffering and deaths among people living with HIV/AIDS, it is unknown how best HAART can be used to reduce the number of new HIV infections. Models would help us determine the best strategy, but we need improved methods of model calibration and analysis to do this.

In this project we will develop new methods to calibrate and analyse complex individual-based stochastic models (these models are very computer-intensive as every individual is explicitly tracked through time). First we will develop two new model calibration methods specifically for stochastic models and also develop new methods that allow us to calibrate multiple models outputs at the same time (eg the number of people infected with HIV and the number of deaths from AIDS). Then we will compare these new methods with existing methods to see how they perform. We will go on to develop hybrid calibration methods that combines the strengths of our new and existing methods, to get the best of both. Finally we will apply our new methods to calibrate a complex model to data on HIV/AIDS trends in Africa, and use our fitted models to predict the impact of HAART on HIV/AIDS in Africa. 

The development and evaluation of robust methods for the calibration and analysis of complex models should result in the generation of more reliable scientific evidence and better health policy and funding decisions. In addition, an effective method of assessing the likely impact of HAART should lead to better informed policies and improved public health in Africa. If the models are accurate, the benefits may include fewer people dying and being infected with HIV, alleviating the substantial social and economic burden of the epidemic as well as reducing the burgeoning costs of HIV-related health care.

An international multidisciplinary team will carry out this research. Statistical expertise is available from investigators from Durham University, Sheffield University and Cambridge University; expertise in the development and application of complex HIV models is available from investigators in the London School of Hygiene and Tropical Medicine; and virologic expertise and uniquely detailed high quality empirical data is available from MRC/UVRI in Uganda.</gtr:abstractText><gtr:technicalSummary>Complex individual-based stochastic models are increasingly being used across science, engineering, medicine and public health. The utility of models for prediction &amp;amp; planning relies on how well they are calibrated to data and analysed for robustness of predictions. However, development of methods to calibrate and analyse complex stochastic models has greatly lagged behind their application, resulting in unreliable predictions and increasing the probability of incorrect policy and funding decisions

Aim
Develop and evaluate methods to calibrate and analyse complex individual-based stochastic models, and apply them to explore the impact of HAART on HIV/AIDS in Africa

Objectives
-Develop novel methods for Bayesian Emulation of stochastic models
-Comparative analysis of accuracy/efficiency of existing MCMC, ABC and novel Bayesian Emulation methods for the calibration and analysis of stochastic models
-Develop and analyse a novel hybrid model calibration strategy combining the strengths of ABC and Emulation methods
-Apply developed and analysed methods to predict the impact of HAART on HIV/AIDS in Africa

Methods
Development: Bayes linear and fully Bayesian emulation for calibration of stochastic models, and multivariate outputs
Hybrid ABC &amp;amp; Emulation methods for efficient generation of probabilistic statements about goodness of fit &amp;amp; joint estimation of posterior probability distributions
Experiments: Use new methods to estimate model parameters by calibrating model to simulated data with known 'true' parameter values, varying number and prior bias &amp;amp; variance of model parameters
Application: Use new methods to calibrate complex model to uniquely detailed HIV/AIDS data from African cohorts

Application/exploitation
Application within project to predict impact of HAART on HIV in Africa and engagement with international policy makers/funders to improve policy/funding decisions. Novel methods dissemination to other science areas/public sector/industry</gtr:technicalSummary><gtr:potentialImpactText>This research should benefit society as a whole, primarily through improved understanding and prediction of complex models, and thereby improved guidance to policy makers.

Immediate beneficiaries will include the users and developers of complex models in government, the public sector, industry and academia. These users will have better methods with which to calibrate and analyse their complex models. Example beneficiaries include epidemiologists and public researchers who use models to compare different strategies to combat infection in the UK and elsewhere, and oil industry engineers who use models to provide information on where to drill exploratory wells. The former is an example where this research could have a relatively quick impact on public heath in the UK and elsewhere. The latter is an example where this research could have a direct and relatively quick impact on the UK economy. Investigators on the proposal have direct links to both groups of beneficiaries.

Direct beneficiaries also include national and international technical modelling committees who will be interested in these developments. An example includes WHO Quantitative Immunisation and Vaccines related Research Committee, on which one of the investigators sits.

This research should also benefit those who rely on information generated by models to make decisions. For example, UK governmental committees such as the UK Joint Committee on Vaccination and Immunisation (JCVI) and international body UNAIDS, both of which rely heavily on information generated by models in their decision making. These bodies would benefit from the higher quality information that could be provided if our novel methods are implemented. Investigators on the proposal are advisors to both these bodies.

The general public should benefit from the improved policy and funding decisions that can be made based on the higher quality information provided by our novel model calibration and analysis methods. They should also benefit from improved policy formation that should lead to improved health and well being, and improved resource allocation in public services.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>515607</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centers for Disease Control and Prevention (CDC)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>TB Modelling and Analysis Consortium</gtr:description><gtr:id>6D12850E-0ECD-40D2-BF3D-EA6EB2D9A4E4</gtr:id><gtr:impact>Huge amount of outputs, please see other sections of report
Publications in Modelling research agenda, TB Diagnostics
Impact on Policy, Govt Budgets, and Research Priorities in South Africa</gtr:impact><gtr:partnerContribution>Has resulted in significant intellectual and in-kind research time of many other research groups input to my groups research (e.g. Global TB Targets work was a collaboration of 11 international research groups contributing results to this research question, largely unfunded).</gtr:partnerContribution><gtr:piContribution>Intellectual and meeting organisational input. 
This consortium funds 50% of my time and 100% of two of my group members (1 research, 1 admin).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bill and Melinda Gates Foundation</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>TB Modelling and Analysis Consortium</gtr:description><gtr:id>AA30C45D-ED57-420A-AB5B-3FE65717B952</gtr:id><gtr:impact>Huge amount of outputs, please see other sections of report
Publications in Modelling research agenda, TB Diagnostics
Impact on Policy, Govt Budgets, and Research Priorities in South Africa</gtr:impact><gtr:partnerContribution>Has resulted in significant intellectual and in-kind research time of many other research groups input to my groups research (e.g. Global TB Targets work was a collaboration of 11 international research groups contributing results to this research question, largely unfunded).</gtr:partnerContribution><gtr:piContribution>Intellectual and meeting organisational input. 
This consortium funds 50% of my time and 100% of two of my group members (1 research, 1 admin).</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard School of Public Health</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>TB Modelling and Analysis Consortium</gtr:description><gtr:id>8F6BE32B-28EC-4B8D-86B5-36261A08B13A</gtr:id><gtr:impact>Huge amount of outputs, please see other sections of report
Publications in Modelling research agenda, TB Diagnostics
Impact on Policy, Govt Budgets, and Research Priorities in South Africa</gtr:impact><gtr:partnerContribution>Has resulted in significant intellectual and in-kind research time of many other research groups input to my groups research (e.g. Global TB Targets work was a collaboration of 11 international research groups contributing results to this research question, largely unfunded).</gtr:partnerContribution><gtr:piContribution>Intellectual and meeting organisational input. 
This consortium funds 50% of my time and 100% of two of my group members (1 research, 1 admin).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ghana Health Service</gtr:collaboratingOrganisation><gtr:country>Ghana, Republic of</gtr:country><gtr:description>In country modelling to support disease control policy making</gtr:description><gtr:id>834DFD4B-C617-4138-BCB8-FF50E79BFE12</gtr:id><gtr:impact>Ghana - altered TB disease control strategy
Viet Nam - contributed to increased funding from Global Fund to TB disease control in Viet Nam</gtr:impact><gtr:partnerContribution>Intellectual and meeting organisational input,</gtr:partnerContribution><gtr:piContribution>Intellectual and meeting organisational input, and modelling expertise fitting models to country disease TB epidemics</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Amsterdam Institute for Global Health and Development (AIGHD)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>TB Diagnostics Forum Modelling Workgroup</gtr:description><gtr:id>2F09FC57-6426-48F9-8719-3934AA826AD9</gtr:id><gtr:impact>Publications. 
Target Product Profiles of new diagnostics.</gtr:impact><gtr:partnerContribution>JHU leads the working group. AIGHD provides scientific input.</gtr:partnerContribution><gtr:piContribution>Intellectual input to discussions on characteristics of desired target product profiles for new diagnostics</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Intellectual Ventures</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>TB Modelling and Analysis Consortium</gtr:description><gtr:id>B5781C75-3E35-4B04-B5C4-543800C19CA8</gtr:id><gtr:impact>Huge amount of outputs, please see other sections of report
Publications in Modelling research agenda, TB Diagnostics
Impact on Policy, Govt Budgets, and Research Priorities in South Africa</gtr:impact><gtr:partnerContribution>Has resulted in significant intellectual and in-kind research time of many other research groups input to my groups research (e.g. Global TB Targets work was a collaboration of 11 international research groups contributing results to this research question, largely unfunded).</gtr:partnerContribution><gtr:piContribution>Intellectual and meeting organisational input. 
This consortium funds 50% of my time and 100% of two of my group members (1 research, 1 admin).</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Johns Hopkins Bloomberg School of Public Health</gtr:department><gtr:description>TB Modelling and Analysis Consortium</gtr:description><gtr:id>F43231E9-88EB-4CEB-B640-6D746BA80D4A</gtr:id><gtr:impact>Huge amount of outputs, please see other sections of report
Publications in Modelling research agenda, TB Diagnostics
Impact on Policy, Govt Budgets, and Research Priorities in South Africa</gtr:impact><gtr:partnerContribution>Has resulted in significant intellectual and in-kind research time of many other research groups input to my groups research (e.g. Global TB Targets work was a collaboration of 11 international research groups contributing results to this research question, largely unfunded).</gtr:partnerContribution><gtr:piContribution>Intellectual and meeting organisational input. 
This consortium funds 50% of my time and 100% of two of my group members (1 research, 1 admin).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Government of Vietnam</gtr:collaboratingOrganisation><gtr:country>Vietnam, Socialist Republic of</gtr:country><gtr:description>In country modelling to support disease control policy making</gtr:description><gtr:id>22B86E26-E062-48CB-A563-9D218FE7D13D</gtr:id><gtr:impact>Ghana - altered TB disease control strategy
Viet Nam - contributed to increased funding from Global Fund to TB disease control in Viet Nam</gtr:impact><gtr:partnerContribution>Intellectual and meeting organisational input,</gtr:partnerContribution><gtr:piContribution>Intellectual and meeting organisational input, and modelling expertise fitting models to country disease TB epidemics</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>World Health Organization (WHO)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>Department of Control of Neglected Tropical Diseases (NTD)</gtr:department><gtr:description>TB Modelling and Analysis Consortium</gtr:description><gtr:id>FAFD80CF-1828-4324-8169-C5113905171E</gtr:id><gtr:impact>Huge amount of outputs, please see other sections of report
Publications in Modelling research agenda, TB Diagnostics
Impact on Policy, Govt Budgets, and Research Priorities in South Africa</gtr:impact><gtr:partnerContribution>Has resulted in significant intellectual and in-kind research time of many other research groups input to my groups research (e.g. Global TB Targets work was a collaboration of 11 international research groups contributing results to this research question, largely unfunded).</gtr:partnerContribution><gtr:piContribution>Intellectual and meeting organisational input. 
This consortium funds 50% of my time and 100% of two of my group members (1 research, 1 admin).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johns Hopkins Medicine</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>TB Diagnostics Forum Modelling Workgroup</gtr:description><gtr:id>0F607FF4-BF48-458A-B1EE-AEA2A7E42C5C</gtr:id><gtr:impact>Publications. 
Target Product Profiles of new diagnostics.</gtr:impact><gtr:partnerContribution>JHU leads the working group. AIGHD provides scientific input.</gtr:partnerContribution><gtr:piContribution>Intellectual input to discussions on characteristics of desired target product profiles for new diagnostics</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Meeting with Uganda Ministry of Health Officials</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5849A667-DCAF-4C69-B61F-0C1DF9359977</gtr:id><gtr:impact>Meeting with Uganda Ministry of Health officials involved with the HIV programme in the country, to present research findings on the potential costs and effects of different ART scale-up activities</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press release - PrEP for HIV in uk MSM</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>901EF4F3-65AB-4001-A1BB-472E3BFBE6D4</gtr:id><gtr:impact>Press release taken up by many global news paper, BBC, newsnight, ...</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.lshtm.ac.uk/newsevents/news/2016/prep_drugs_could_reverse_hiv_epidemic.html</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Newsnight lead story - PrEP for HIV in uk MSM</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D9311B1E-8731-41EC-8BA3-EF27B71E9170</gtr:id><gtr:impact>BBC Newsnight lead item. Video: Intro &amp;amp; WHITE, WHITE excerpts + BBC website, &amp;amp; many newspapers incl Guardian, Telegraph. Prep for HIV in UK MSM. Jan 15th 2016</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>https://drive.google.com/open?id=0B2K5XWn1bjpOQTJLRXpNMDBTdUU</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Emulation workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E1F66F0A-16E1-4BED-B003-26F8E82A69BF</gtr:id><gtr:impact>We organised a workshop for 30 participants who attended a 1 day hands on workshop which showcased the research methodology that is being developed in this project. Special software was prepared that allowed the participants to try out the methods in their own laptops during the workshop.

The workshop places were filled up within two days and there was strong encouragement for a second edition, which we plan to run in 2015.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>https://sites.google.com/site/emulationday/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Tipping points in health and society - public workshop on uncertainty in health.</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BE66CD28-F829-48C1-99EB-692CA5A915B5</gtr:id><gtr:impact>A lot of interest, many questions and an increased awareness of the potential and limitations of public health models, and their associated uncertainty.


Participants showed an appreciation of the impact of uncertainty in public health models.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.esrc.ac.uk/news-and-events/events/festival/festival-events/general-public/Tipping-Points-Health-Society.aspx</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Fellowship</gtr:description><gtr:end>2019-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>109949/Z/15/Z</gtr:fundingRef><gtr:id>A82AFF33-43B8-492D-B0EE-61CF0490C0F2</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Bill and Melinda Gates Foundation: Global Health: Tuberculosis</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:fundingRef>OPP1110334</gtr:fundingRef><gtr:id>70E5CAE2-9B2B-4624-B391-67DC2F42F00F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>386998</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2019-02-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:id>506BAFB4-5A4A-4429-B90D-AF33C84AA622</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2017-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>287454</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Fellowship (by team member)</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:fundingRef>MR/N014693/1</gtr:fundingRef><gtr:id>F49EDF1E-8874-41EB-BCBB-B23ED664A645</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Aeras studentship grant</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Aeras</gtr:fundingOrg><gtr:id>36FA2072-527E-4199-A9BE-B83E5C90DE1A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>Hungary, Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Bristish Heart Foundation Fellowship</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Heart Centre Foundation, Hungary</gtr:fundingOrg><gtr:id>EF1E9BAA-AC11-42E7-A166-DB5FF24523B8</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2300000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Bill and Melinda Gates Foundation: Global Health: Tuberculosis</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:fundingRef>OPP1084276</gtr:fundingRef><gtr:id>DADBE6B7-4BF0-42E1-9FD6-60212354F988</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Bill and Melinda Gates Foundation: Global Health: Tuberculosis</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>68770297-FDE5-4410-AEF6-73A67109A844</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2709550</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UNITAID</gtr:department><gtr:description>UNITAID Reserach Grant</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>World Health Organization (WHO)</gtr:fundingOrg><gtr:fundingRef>4214-LSHTM-Sept15 (PO #8477-0-600)</gtr:fundingRef><gtr:id>E5EABC10-3F5D-48BF-AEF6-4D56A14EE089</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Bill and Melinda Gates Foundation: Global Health: Tuberculosis</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>6416A19F-22C3-4838-9ADD-A8BB45FF4E0A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1499000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>USAID TB Treat Grant</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>United States Agency for International Development</gtr:fundingOrg><gtr:fundingRef>GHN-A-OO-08-00004-00</gtr:fundingRef><gtr:id>8133FCD5-1C67-4C70-8DB7-CE2FB4CCC2F2</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90848</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BMGF project grant</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Bill and Melinda Gates Foundation</gtr:fundingOrg><gtr:id>3982D23B-CBB4-4B8D-86DA-F0A517D9BFFE</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Aeras project grant</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Aeras</gtr:fundingOrg><gtr:id>03BAE21C-1B17-4E06-BBD6-92178AEE0BAC</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We created a user-friendly tool (a mathematical model) for TB-HIV control projections and costing. This tool will be freely available for download by country-level TB/HIV policy makers for decision making on TB control strategies and costing in 2015. It has been used in workshops run by UNAIDS, the Global Fund, WHO and at country level.</gtr:description><gtr:id>2FE0E901-A292-4E47-853C-A2825CAFB4EF</gtr:id><gtr:impact>I was released globally in 2015. So far used to update Sudan, Bangladesh and Vietnam National Strategic Plan in 2013/4 (in Sudan: it led to a move to more decentralized provision of TB patient care), and in South Africa, Ghana and Nigeria. It will be used in about ~5 more high TB burden countries in 2016.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:protection>Copyrighted (e.g. software)</gtr:protection><gtr:title>New user-friendly country-level tool for TB-HIV control projections and costings</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Global Fund Distribution of Funding by Disease</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>6D8C1C2C-1D3B-4C60-A86B-E06BBE07E4CD</gtr:id><gtr:impact>I directly contributed to debate and the (eventual) consensus that led to an increase in proportion of funds allocated by the Global Fund to Tuberculosis. Global reach. Should increase survival and morbidity by reducing TB disease (no quantitative evidence yet)</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Impact on human TB vaccine development funding priorities</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>1F07B8F9-234B-4D6B-AFBE-547C2F836348</gtr:id><gtr:impact>My group helped demonstrate that an new TB vaccine targeted at adolescent/adults would have considerably greater early impact on the global TB epidemic, than a vaccine targeted at infants, and would be cost-effective, even with a relative low efficacy and short protection duration (Knight et al 2015). 
This evidence led to a major change in BMGF TB vaccine policy and was cited to support the primary new BMGF TB vaccine strategy goal: &amp;quot;To accelerate discovery and development of a vaccine to prevent TB infection and/or disease in adolescents and adults&amp;quot; (2014-2015). (url below)</gtr:impact><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type><gtr:url>https://drive.google.com/file/d/0B2K5XWn1bjpORmpHLUdoOXJFTlk/view</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Changed South African Govt Policy Announcement on TB screening in schools</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3548E777-8D14-4A3C-A601-0F66204A25E1</gtr:id><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Input into Global Fund Steering Committee on Modeling work to inform development of the Global Fund's Strategy goals &amp;amp; targets, Needs Assessment and Funding Allocation</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>BCC3F1FA-27CE-4EDC-ADAF-0959C685A3AB</gtr:id><gtr:impact>Methods agreed with input from my group into Global Fund Steering Committee on Modeling work to inform development of the Global Fund's Strategy goals &amp;amp; targets, Needs Assessment and Funding Allocation (2015) were used to prevent inappropriate methods being used to assess Global Fund's strategy goals &amp;amp; targets, needs assessment and funding allocation in 2016+. Specifically inappropriate methods were being considered for between-country resource allocation of the Global Funds TB funds. Use of these methods was prevented.</gtr:impact><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Led creation of 'STROBE-RDS': Reporting Guidelines for Respondent Driven Sampling Surveys</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>17753DF8-0D8D-4A7E-9E08-9F5B387EDD29</gtr:id><gtr:impact>Peer reviewed reporting guidelines have been published, have been incorporated into submission guidelines for at least two academic journals (2016), have already been cited in papers reporting findings from RDS surveys. 
This will increase the value of data collected using RDS. This should lead to improved health and funding decisions targeted (primarily) at the control and prevention of HIV, and later, improved survival, morbidity and quality of life, and the efficiency of health care delivery.</gtr:impact><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/26112433</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>WHO/South African Department of Health Tuberculosis Meeting</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>FDA747E8-E680-4981-81D5-0851C4AEA924</gtr:id><gtr:impact>This and subsequent meetings lead to a change in the South Africa Govt's National Strategic Plan policy to include continuous Isoniazid Preventive Therapy (IPT) to HIV infected individuals. IPT greatly reduces mortality in HIV infected individuals. This will have a near immediate impact on survival / morbidity / quality of life in HIV+ South Africans.</gtr:impact><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Policy recommendation document to Ugandan Ministry of Health</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>0549BEE7-D5DC-4DD3-A1D9-83CAD2D7ACE6</gtr:id><gtr:impact>We had a meeting with Uganda Ministry of Health Officials, and subsequently provided them with a policy recommendation document which they requested. We advised that adopting universal access to ART for all people living with HIV would be highly cost effective, and may be cost saving. Subsequent to this, the Uganda MoH revised its ART guidelines to recommend that ART be provided to all people living with HIV.</gtr:impact><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Impact on TB control funding priorities and budget in South Africa</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0C7A58E2-C9D6-4D18-8DC4-2BA39116A112</gtr:id><gtr:impact>'2025 Global TB Targets' modelling for South Africa is influencing TB policy decisions in this countries (2014+). Where work is influencing SA Govt Budgets, Policy and Research Priorities. This work supported successful award of Global Fund Concept note and grant in 2015, and work was also used in first ever Govt/UNAIDS HIV and TB Investment Case, that supported the introduction of the first ever conditional (ie ringfenced) grant for TB and HIV in SA, and the allocation of an extra Rand500m (~&amp;pound;50m) to TB control by the SA Govt in 2016.</gtr:impact><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Course - Introduction to impact and economics of TB control</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>DA75DD2D-3CDD-46F8-9060-EC54D8BA9EFF</gtr:id><gtr:impact>Trained medical professionals in quantitative methods to use in their decision making at country and global level.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Input into WHO Global Task Force on TB Impact Measurement Reference Methods Group</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>34CD4F23-9F64-40C6-8502-DB72F60E1440</gtr:id><gtr:impact>Methods agreed with input from my group into WHO Global Task Force on TB Impact Measurement Reference Methods Group (2015) were used to determine if the WHO 2000-2015 global TB targets had been met. Published in 2015 WHO TB report. This also helped identify that TB is now the leading cause of death from an infectious disease globally, which should increase global resource allocation to TB over the next few years.</gtr:impact><gtr:type>Participation in a advisory committee</gtr:type><gtr:url>http://www.who.int/tb/publications/global_report/en/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Evidence used to set WHO post-2015 Global TB Targets</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>A11FB843-B636-4963-953A-EDBA973DE500</gtr:id><gtr:impact>My group generated evidence that was used to set ambitious WHO post 2015 global TB targets. This should have major impact on TB financing and control policies and practice over the next 15 years.</gtr:impact><gtr:type>Citation in other policy documents</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>The developed method allows the calibration of multi-input, multi-output agent based computer models of high complexity. The method is based on a statistical approximation of the computer model, called the emulator, and tries to identify regions of the input space that are likely to lead to a match between the model's outputs and the calibration data. The computational efficiency of the emulator makes this method very applicable to computer models with long running times.</gtr:description><gtr:id>85EC2FCD-E9A5-4413-AEBE-B7FE99DD11EF</gtr:id><gtr:impact>None yet</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>History matching of complex agent based computer models using emulation</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:url>http://cmmid.lshtm.ac.uk/mrccalib/</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>We created a user-friendly tool (a mathematical model) for TB-HIV control projections and costing. This tool is for use by country-level TB/HIV policy makers for decision making on TB control strategies and costing. It has been used in workshops at Global level by UNAIDS, the Global Fund and WHO, and at country level in South Africa, Viet Nam, Ghana, Nigeria.</gtr:description><gtr:id>A1DFA7A1-0F69-4E6B-AF54-D05D9C461F57</gtr:id><gtr:impact>It was rolled out globally in 2015. So far it has been used by my group to update the Sudan, Bangladesh and Vietnam National Strategic Plan in 2013/4 (in Sudan, a move to more decentralized provision of TB patient care), and in Ghana, Nigeria. It will be used in about ~5 more high TB burden countries in 2016.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>New user-friendly country-level modelling tool for TB-HIV control projections and costings</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:url>http://www.avenirhealth.org/software-spectrum</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>In high density urban settings without formal address systems, identification of the place of residence of patients presenting to health centres is often challenging and inaccurate. This type of information is essential for patient follow up in the community, for disease surveillance and identification of hotspots for efficient targeting of limited healthcare resources, for research study participant follow up and mapping, and for identifying populations suitable for enrolment into vaccine clinical trials. ePAL (electronic PArticipant Locator tool) is a tablet-based tool aiming to facilitate accurate identification of place of residence of patients presenting to health centres in Blantyre, Malawi. Points of interest relevant to the community were collected using GPS from across Blantyre city by community engagement through health surveillance assistants. Preceded by an eCRF, these points of interest combined with high resolution satellite maps constitute the ePAL app, which is being placed on tablets in TB registration centres across Blantyre city. ePAL is currently being evaluated in this setting and is hoped will be the first electronic data capture of TB registrations in Malawi and an important tool embraced by the Department of Health and Malawi-Liverpool-Wellcome (MLW) research centre for mapping and follow up of TB cases and identification of populations suitable for research including clinical trials. The tool is being developed in collaboration between LSHTM (London, UK) and MLW (Blantyre, Malawi).</gtr:description><gtr:id>832F7D0B-2416-4898-A40D-53A4F8B173F6</gtr:id><gtr:impact>The tool itself has undergone validation for identifying place of residence of TB patients presenting at TB registration centres and the data are currently being analysed. The tool has been adapted for two other research projects at MLW: surveillance for an ongoing typhoid outbreak and a study on impact of PCV vaccines. Several other studies in Blantyre are soon to begin using ePAL. It is hoped once the tool is validated that it could be replicated in other similar settings.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>TB ePAL (electronic PArticipant Locator tool)</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>The developed method allows the calibration of multi-input, multi-output agent based computer models of high complexity. The method is based
on a statistical approximation of the computer model, called the emulator, and tries to identify regions of the input space that are likely to lead to
a match between the model's outputs and the calibration data. The computational efficiency of the emulator makes this method very applicable to
computer models with long running times.</gtr:description><gtr:id>1009B9E1-3845-4272-8173-D973B1C13A03</gtr:id><gtr:impact>None yet</gtr:impact><gtr:openSourceLicense>true</gtr:openSourceLicense><gtr:title>History matching of complex agent based computer models using emulation</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://cmmid.lshtm.ac.uk/mrccalib/</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>In high density urban settings without formal address systems, identification of the place of residence of patients presenting to health centres is often challenging and inaccurate. This type of information is essential for patient follow up in the community, for disease surveillance and identification of hotspots for efficient targeting of limited healthcare resources, for research study participant follow up and mapping, and for identifying populations suitable for enrolment into vaccine clinical trials. ePAL (electronic PArticipant Locator tool) is a tablet-based tool aiming to facilitate accurate identification of place of residence of patients presenting to health centres in Blantyre, Malawi. Points of interest relevant to the community were collected using GPS from across Blantyre city by community engagement through health surveillance assistants. Preceded by an eCRF, these points of interest combined with high resolution satellite maps constitute the ePAL app, which is being placed on tablets in TB registration centres across Blantyre city. ePAL is currently being evaluated in this setting and is hoped will be the first electronic data capture of TB registrations in Malawi and an important tool embraced by the Department of Health and Malawi-Liverpool-Wellcome (MLW) research centre for mapping and follow up of TB cases and identification of populations suitable for research including clinical trials. The tool is being developed in collaboration between LSHTM (London, UK) and MLW (Blantyre, Malawi).</gtr:description><gtr:id>6749842F-8306-4DA5-A134-2E135C353E55</gtr:id><gtr:impact>The tool itself has undergone validation for identifying place of residence of TB patients presenting at TB registration centres and the data are currently being analysed. The tool has been adapted for two other research projects at MLW: surveillance for an ongoing typhoid outbreak and a study on impact of PCV vaccines. Several other studies in Blantyre are soon to begin using ePAL. It is hoped once the tool is validated that it could be replicated in other similar settings.</gtr:impact><gtr:title>TB ePAL (electronic PArticipant Locator tool)</gtr:title><gtr:type>Webtool/Application</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>We created a user-friendly tool (a mathematical model) for TB-HIV control projections and costing. This tool is for use by country-level TB/HIV
policy makers for decision making on TB control strategies and costing. It has been used in workshops run by UNAIDS, the Global Fund and WHO
over the coming years.</gtr:description><gtr:id>DF0DBFEF-8A28-413D-B64D-47F86066A7AB</gtr:id><gtr:impact>It was released globally in 2015. So far used to update the Government of Sudan, Bangladesh and Vietnam National Strategic Plan in 2013/4 (in Sudan, a move to more decentralized provision of TB patient care), South Africa, Ghana and Nigeria. It will be used in ~5 more high TB burden countries in 2016.</gtr:impact><gtr:openSourceLicense>true</gtr:openSourceLicense><gtr:title>New user-friendly country-level modelling tool for TB-HIV control projections and costings</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://www.avenirhealth.org/software-spectrum</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Avenir Health</gtr:companyName><gtr:description>Futures Institute, founded in 2006, is a global health organization that works to enhance social and economic development by providing tools and technical assistance in policy, planning, resource allocation and evaluation. In particular, we focus on developing and implementing demographic, epidemiological and costing models for long-range planning to assist with setting goals, strategies, and objectives. We assist in both developing and implementing programs in HIV/AIDS, reproductive health, maternal health and other programming areas. We work with government agencies, foundations, corporations, and nongovernmental organizations around the world.

Areas of program concentration include family planning and reproductive health, maternal and child health, the prevention and treatment of HIV/AIDS, and infectious diseases. With staff based in the United States and Africa, we work collaboratively with our in-country counterparts to improve policies and programs that address population issues, reproductive health, HIV/AIDS, infectious diseases, and maternal and child health.</gtr:description><gtr:id>9FFB881D-7A95-4C64-9FD7-C3BDF7CD978C</gtr:id><gtr:impact>Impacts are many and varied across a variety of health sectors. 
Impacts that my (Tuberculosis) work with them has supported includes:
1) generating country-level TB/HIV estimates for the WHO report 2013 and 2014, 
3) Generating evidence for the STOPTB/WHO Tuberculosis Global Plan (2015) - global resource needs estimates, that are used to motivate for funding from international partners (Gates, Global Fund, ...)
3) Futures working with countries to develop TB/HIV National Strategic Plans in 3+ countries globally, affecting governmental TB/HIV strategies and resource allocation within these 3 countries. 
This is an active and growing collaboration and much more activity will happen over the next 12 months.</gtr:impact><gtr:url>http://www.avenirhealth.org/</gtr:url><gtr:yearCompanyFormed>2006</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4A229394-CD26-48DD-A535-F61268F08AF0"><gtr:id>4A229394-CD26-48DD-A535-F61268F08AF0</gtr:id><gtr:title>Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/86560785fbb86bc81239d01fd9616525"><gtr:id>86560785fbb86bc81239d01fd9616525</gtr:id><gtr:otherNames>Horton KC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E0A0EB6E-DCED-492D-8234-43182B6C4A64"><gtr:id>E0A0EB6E-DCED-492D-8234-43182B6C4A64</gtr:id><gtr:title>Estimation of the HIV basic reproduction number in rural south west Uganda: 1991-2008.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/99395ac8117237f19900fd97f4502674"><gtr:id>99395ac8117237f19900fd97f4502674</gtr:id><gtr:otherNames>Nsubuga RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/79AE5CF8-EC94-4E28-A07E-1D27DA0747E8"><gtr:id>79AE5CF8-EC94-4E28-A07E-1D27DA0747E8</gtr:id><gtr:title>Predicting the long-term impact of antiretroviral therapy scale-up on population incidence of tuberculosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a8fa3e311c4f6e1e8f3a5e0ddf1c1d88"><gtr:id>a8fa3e311c4f6e1e8f3a5e0ddf1c1d88</gtr:id><gtr:otherNames>Dodd PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/58F53249-5E2C-467A-9C18-D71B4704C9EF"><gtr:id>58F53249-5E2C-467A-9C18-D71B4704C9EF</gtr:id><gtr:title>Modelling the HIV epidemic among MSM in the United Kingdom: quantifying the contributions to HIV transmission to better inform prevention initiatives.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c113baf3e8d44f6e5888d0d5a61caf2"><gtr:id>4c113baf3e8d44f6e5888d0d5a61caf2</gtr:id><gtr:otherNames>Punyacharoensin N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E146F1B2-0D06-4313-9B45-17B2988DF33A"><gtr:id>E146F1B2-0D06-4313-9B45-17B2988DF33A</gtr:id><gtr:title>History matching of a complex epidemiological model of human immunodeficiency virus transmission by using variance emulation</gtr:title><gtr:parentPublicationTitle>Journal of the Royal Statistical Society: Series C (Applied Statistics)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e7274488260ddc258bbee065fa1edd48"><gtr:id>e7274488260ddc258bbee065fa1edd48</gtr:id><gtr:otherNames>Andrianakis I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/133BAC70-55C6-4EA1-A725-F2468ECE9161"><gtr:id>133BAC70-55C6-4EA1-A725-F2468ECE9161</gtr:id><gtr:title>The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa: results from three tuberculosis-HIV transmission models.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/29c8c2e55290f83c8645b954dd2ca494"><gtr:id>29c8c2e55290f83c8645b954dd2ca494</gtr:id><gtr:otherNames>Pretorius C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB341EAC-C055-43D0-AE1D-6935688F9C53"><gtr:id>AB341EAC-C055-43D0-AE1D-6935688F9C53</gtr:id><gtr:title>The transmission of Mycobacterium tuberculosis in high burden settings.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/555aedc1c0a8cad1524997adb12aa924"><gtr:id>555aedc1c0a8cad1524997adb12aa924</gtr:id><gtr:otherNames>Yates TA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1E74FCDB-336E-4F78-9245-50970A5661AE"><gtr:id>1E74FCDB-336E-4F78-9245-50970A5661AE</gtr:id><gtr:title>The effect of diabetes and undernutrition trends on reaching 2035 global tuberculosis targets.</gtr:title><gtr:parentPublicationTitle>The lancet. Diabetes &amp; endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9640e5ec0a493562ad2a4bee17ef9cc7"><gtr:id>9640e5ec0a493562ad2a4bee17ef9cc7</gtr:id><gtr:otherNames>Odone A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2213-8587</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/76C4366C-2E00-44C2-8EB1-27776BA3F377"><gtr:id>76C4366C-2E00-44C2-8EB1-27776BA3F377</gtr:id><gtr:title>HIV treatment as prevention: models, data, and questions--towards evidence-based decision-making.</gtr:title><gtr:parentPublicationTitle>PLoS medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d28909ebe82b39dc80b1efdcfd80540f"><gtr:id>d28909ebe82b39dc80b1efdcfd80540f</gtr:id><gtr:otherNames>HIV Modelling Consortium Treatment as Prevention Editorial Writing Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1549-1277</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2900E7C0-6D87-4419-85B0-324D91692365"><gtr:id>2900E7C0-6D87-4419-85B0-324D91692365</gtr:id><gtr:title>Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d1f5ea08d6d4b36866447215e036b04b"><gtr:id>d1f5ea08d6d4b36866447215e036b04b</gtr:id><gtr:otherNames>Fofana MO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/833253A2-162A-4FE3-B486-AE667750A829"><gtr:id>833253A2-162A-4FE3-B486-AE667750A829</gtr:id><gtr:title>Tuberculosis prevention in South Africa.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/315910c155481b784196777afe33f4a5"><gtr:id>315910c155481b784196777afe33f4a5</gtr:id><gtr:otherNames>Knight GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/94C90863-1820-401B-8853-37CB3C0E50A2"><gtr:id>94C90863-1820-401B-8853-37CB3C0E50A2</gtr:id><gtr:title>Developing whole mycobacteria cell vaccines for tuberculosis: Workshop proceedings, Max Planck Institute for Infection Biology, Berlin, Germany, July 9, 2014.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f3aa1cb572043df4499ac8cacf13ba96"><gtr:id>f3aa1cb572043df4499ac8cacf13ba96</gtr:id><gtr:otherNames>Whole Mycobacteria Cell Vaccines for Tuberculosis Summary Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C9B61407-D8DC-4945-8BDE-8F8268530980"><gtr:id>C9B61407-D8DC-4945-8BDE-8F8268530980</gtr:id><gtr:title>Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/315910c155481b784196777afe33f4a5"><gtr:id>315910c155481b784196777afe33f4a5</gtr:id><gtr:otherNames>Knight GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/198E9D0C-F6B3-46DB-A9AA-1C1366F78729"><gtr:id>198E9D0C-F6B3-46DB-A9AA-1C1366F78729</gtr:id><gtr:title>The impact of antiretroviral therapy on mortality in HIV positive people during tuberculosis treatment: a systematic review and meta-analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9640e5ec0a493562ad2a4bee17ef9cc7"><gtr:id>9640e5ec0a493562ad2a4bee17ef9cc7</gtr:id><gtr:otherNames>Odone A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/055B8F40-BA8D-4BEB-8C33-28F619799805"><gtr:id>055B8F40-BA8D-4BEB-8C33-28F619799805</gtr:id><gtr:title>Impact and cost-effectiveness of current and future tuberculosis diagnostics: the contribution of modelling.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c99bfb9e657c7eb39620400bc2d0afa7"><gtr:id>c99bfb9e657c7eb39620400bc2d0afa7</gtr:id><gtr:otherNames>Dowdy DW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C5A4227A-3B9E-40FB-84EE-ABCA16582579"><gtr:id>C5A4227A-3B9E-40FB-84EE-ABCA16582579</gtr:id><gtr:title>The Impact and Cost-Effectiveness of a Four-Month Regimen for First-Line Treatment of Active Tuberculosis in South Africa.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/315910c155481b784196777afe33f4a5"><gtr:id>315910c155481b784196777afe33f4a5</gtr:id><gtr:otherNames>Knight GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/072FEADA-8C9E-4A8D-B5A9-C0D30BE9F69C"><gtr:id>072FEADA-8C9E-4A8D-B5A9-C0D30BE9F69C</gtr:id><gtr:title>Effect of HSV-2 on population-level trends in HIV incidence in Uganda between 1990 and 2007.</gtr:title><gtr:parentPublicationTitle>Tropical medicine &amp; international health : TM &amp; IH</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ec9b47f4af9d5dd9675d99f15f30a319"><gtr:id>ec9b47f4af9d5dd9675d99f15f30a319</gtr:id><gtr:otherNames>Biraro S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1360-2276</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AE346ED2-1B6D-437F-9601-5094698C4FA1"><gtr:id>AE346ED2-1B6D-437F-9601-5094698C4FA1</gtr:id><gtr:title>Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ab4232cff6ff6be6197e48bed092674f"><gtr:id>ab4232cff6ff6be6197e48bed092674f</gtr:id><gtr:otherNames>Houben RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D4D76FD3-EC30-46DB-8AC3-E485025D8C88"><gtr:id>D4D76FD3-EC30-46DB-8AC3-E485025D8C88</gtr:id><gtr:title>Looking upstream to prevent HIV transmission: can interventions with sex workers alter the course of HIV epidemics in Africa as they did in Asia?</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d55768d6cb7453a96823795351486cbf"><gtr:id>d55768d6cb7453a96823795351486cbf</gtr:id><gtr:otherNames>Steen R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/77AE16DE-DE2B-46DD-9A47-DA5310DEFE89"><gtr:id>77AE16DE-DE2B-46DD-9A47-DA5310DEFE89</gtr:id><gtr:title>Drivers and trajectories of resistance to new first-line drug regimens for tuberculosis.</gtr:title><gtr:parentPublicationTitle>Open forum infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9e403c7c2af84f18a0ef7e771e296abc"><gtr:id>9e403c7c2af84f18a0ef7e771e296abc</gtr:id><gtr:otherNames>Shrestha S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2328-8957</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A4C608B7-5F5C-4233-8EA0-ED26E1244263"><gtr:id>A4C608B7-5F5C-4233-8EA0-ED26E1244263</gtr:id><gtr:title>Effect of pre-exposure prophylaxis and combination HIV prevention for men who have sex with men in the UK: a mathematical modelling study.</gtr:title><gtr:parentPublicationTitle>The lancet. HIV</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c113baf3e8d44f6e5888d0d5a61caf2"><gtr:id>4c113baf3e8d44f6e5888d0d5a61caf2</gtr:id><gtr:otherNames>Punyacharoensin N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2352-3018</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DD6D39AE-C607-424A-8E41-41AFFFF1F929"><gtr:id>DD6D39AE-C607-424A-8E41-41AFFFF1F929</gtr:id><gtr:title>Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.</gtr:title><gtr:parentPublicationTitle>The Lancet. Global health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/df45bbde2fa354f91b34a4853de41aac"><gtr:id>df45bbde2fa354f91b34a4853de41aac</gtr:id><gtr:otherNames>Eaton JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2214-109X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B1A42286-A387-4212-A047-A2B5080EBE2B"><gtr:id>B1A42286-A387-4212-A047-A2B5080EBE2B</gtr:id><gtr:title>Modeling of novel diagnostic strategies for active tuberculosis - a systematic review: current practices and recommendations.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8beeebc1b4df2e53955a561c18ee4b83"><gtr:id>8beeebc1b4df2e53955a561c18ee4b83</gtr:id><gtr:otherNames>Zwerling A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/30A8F17C-68CA-47AB-8538-D4E2911ADA25"><gtr:id>30A8F17C-68CA-47AB-8538-D4E2911ADA25</gtr:id><gtr:title>The potential impact of BCG vaccine supply shortages on global paediatric tuberculosis mortality.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/469e2ca4b35e270ecb32c2caf6598e94"><gtr:id>469e2ca4b35e270ecb32c2caf6598e94</gtr:id><gtr:otherNames>Harris RC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EB6A1B57-CDF3-46AB-9C93-75B395A17A52"><gtr:id>EB6A1B57-CDF3-46AB-9C93-75B395A17A52</gtr:id><gtr:title>Bayesian history matching of complex infectious disease models using emulation: a tutorial and a case study on HIV in Uganda.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e7274488260ddc258bbee065fa1edd48"><gtr:id>e7274488260ddc258bbee065fa1edd48</gtr:id><gtr:otherNames>Andrianakis I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/05238C82-F1B8-42F1-8B51-FB4ADFAED8C6"><gtr:id>05238C82-F1B8-42F1-8B51-FB4ADFAED8C6</gtr:id><gtr:title>Accelerating progress towards tuberculosis elimination: the need for combination treatment and prevention.</gtr:title><gtr:parentPublicationTitle>The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f409e6effa963165e88c95c6b2a649eb"><gtr:id>f409e6effa963165e88c95c6b2a649eb</gtr:id><gtr:otherNames>Reid A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1027-3719</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/541B6288-C21B-4101-9EC7-DAD82B7AB2F7"><gtr:id>541B6288-C21B-4101-9EC7-DAD82B7AB2F7</gtr:id><gtr:title>Age- and Sex-Specific Social Contact Patterns and Incidence of Mycobacterium tuberculosis Infection.</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a8fa3e311c4f6e1e8f3a5e0ddf1c1d88"><gtr:id>a8fa3e311c4f6e1e8f3a5e0ddf1c1d88</gtr:id><gtr:otherNames>Dodd PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E305BE2C-DD9D-409B-99F3-F818D8556A15"><gtr:id>E305BE2C-DD9D-409B-99F3-F818D8556A15</gtr:id><gtr:title>Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: &amp;quot;STROBE-RDS&amp;quot; statement.</gtr:title><gtr:parentPublicationTitle>Journal of clinical epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9671f0547378b4422b992b3ea8b9c2b2"><gtr:id>9671f0547378b4422b992b3ea8b9c2b2</gtr:id><gtr:otherNames>White RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0895-4356</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/3DF43168-50A7-4EAE-BBBE-947264972E50"><gtr:id>3DF43168-50A7-4EAE-BBBE-947264972E50</gtr:id><gtr:title>Using the TIME model in Spectrum to estimate tuberculosis-HIV incidence and mortality.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/29c8c2e55290f83c8645b954dd2ca494"><gtr:id>29c8c2e55290f83c8645b954dd2ca494</gtr:id><gtr:otherNames>Pretorius C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DC1356CD-BB86-4794-AB4A-DED9D7107426"><gtr:id>DC1356CD-BB86-4794-AB4A-DED9D7107426</gtr:id><gtr:title>TIME Impact - a new user-friendly tuberculosis (TB) model to inform TB policy decisions.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ab4232cff6ff6be6197e48bed092674f"><gtr:id>ab4232cff6ff6be6197e48bed092674f</gtr:id><gtr:otherNames>Houben RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5BF1BCFF-895C-4539-B6C6-86E373E9D481"><gtr:id>5BF1BCFF-895C-4539-B6C6-86E373E9D481</gtr:id><gtr:title>Developing vaccines to prevent sustained infection with Mycobacterium tuberculosis: Conference proceedings: National Institute of Allergy and Infectious Diseases, Rockville, Maryland USA, November 7, 2014.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1634a24220168494275c317e6a63b60b"><gtr:id>1634a24220168494275c317e6a63b60b</gtr:id><gtr:otherNames>Vaccine Prevention of Sustained Mycobacterium tuberculosis Infection Summary Group</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/083FEB48-FD24-40F7-A3C5-3EDBAD0C2D09"><gtr:id>083FEB48-FD24-40F7-A3C5-3EDBAD0C2D09</gtr:id><gtr:title>Risk factors associated with Rift Valley fever epidemics in South Africa in 2008-11.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2f0498ce56338356b43a234d102ad97f"><gtr:id>2f0498ce56338356b43a234d102ad97f</gtr:id><gtr:otherNames>M?tras R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2550C16E-6EA6-4115-99FC-A2C8300C41F0"><gtr:id>2550C16E-6EA6-4115-99FC-A2C8300C41F0</gtr:id><gtr:title>The dual impact of antiretroviral therapy and sexual behaviour changes on HIV epidemiologic trends in Uganda: a modelling study.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted infections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/92b8de042e1b2ed47584a5aca506c015"><gtr:id>92b8de042e1b2ed47584a5aca506c015</gtr:id><gtr:otherNames>Shafer LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1368-4973</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2C03A8D3-B19E-4B26-B729-6D7CF3635452"><gtr:id>2C03A8D3-B19E-4B26-B729-6D7CF3635452</gtr:id><gtr:title>The Distribution of Fitness Costs of Resistance-Conferring Mutations Is a Key Determinant for the Future Burden of Drug-Resistant Tuberculosis: A Model-Based Analysis.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/315910c155481b784196777afe33f4a5"><gtr:id>315910c155481b784196777afe33f4a5</gtr:id><gtr:otherNames>Knight GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D9403C00-9338-443B-9F9C-938C95110DB7"><gtr:id>D9403C00-9338-443B-9F9C-938C95110DB7</gtr:id><gtr:title>Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/60bf848ab57bb15e4f42b16ad7de6073"><gtr:id>60bf848ab57bb15e4f42b16ad7de6073</gtr:id><gtr:otherNames>Rhodes SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/96605897-4366-4E18-B909-32B4F17653A1"><gtr:id>96605897-4366-4E18-B909-32B4F17653A1</gtr:id><gtr:title>Bayesian history matching of complex infectious disease models using emulation: a tutorial and a case study on HIV in Uganda.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e7274488260ddc258bbee065fa1edd48"><gtr:id>e7274488260ddc258bbee065fa1edd48</gtr:id><gtr:otherNames>Andrianakis I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J005088/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>FB395309-E202-4FE8-87B0-041A3D72D4D4</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.5  Research design and methodologies (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>